ANI Pharmaceuticals, Inc. (ANIP)
NASDAQ: ANIP · Real-Time Price · USD
81.20
+1.07 (1.34%)
At close: Jun 9, 2026, 4:00 PM EDT
80.01
-1.19 (-1.47%)
After-hours: Jun 9, 2026, 6:56 PM EDT

ANI Pharmaceuticals Stock Forecast

Stock Price Forecast

According to 8 analysts polled by S&P Global, ANI Pharmaceuticals stock has a consensus rating of "Buy" and an average price target of $109.88. The average 1-year stock price forecast is 35.32% higher than the current stock price, while the lowest is $90 (+10.84%) and the highest is $124 (+52.71%).

Price Target: $109.88 (+35.32%)
Analyst Consensus: Buy
TargetLowAverageMedianHigh
Price$90$109.88$110$124
Change+10.84%+35.32%+35.47%+52.71%

Analyst Ratings

The average analyst rating for ANI Pharmaceuticals stock is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.

Recommendation Trends

RatingDec '25Jan '26Feb '26Mar '26Apr '26May '26
Strong Buy444444
Buy333333
Hold111111
Sell000000
Strong Sell000000
Total888888

Latest Forecasts

AnalystFirmRatingRatingActionPrice TargetUpsideDate
Barclays
Barclays
Buy
Maintains
$100
BuyMaintains$100+23.15%May 20, 2026
Truist Financial
Truist Financial
Hold
Maintains
n/a
HoldMaintainsn/an/aMay 11, 2026
Guggenheim
Guggenheim
Buy
Reiterates
$124
BuyReiterates$124+52.71%May 11, 2026
H.C. Wainwright
H.C. Wainwright
Buy
Reiterates
$121
BuyReiterates$121+49.01%May 8, 2026
Unknown Analyst
J.P. Morgan
No rating
J.P. Morgan
Buy
Maintains
n/a
BuyMaintainsn/an/aMay 8, 2026
More Analyst Ratings

Financial Forecast

Revenue This Year
1.12B
from 883.37M
Increased by 27.07%
Revenue Next Year
1.25B
from 1.12B
Increased by 11.22%
EPS This Year
9.40
from 7.89
Increased by 19.08%
EPS Next Year
10.61
from 9.40
Increased by 12.94%
Fiscal YearFY 2021FY 2022FY 2023FY 2024FY 2025FY 2026
Period EndingDec 31, 2021Dec 31, 2022Dec 31, 2023Dec 31, 2024Dec 31, 2025Dec 31, 2026
Revenue
216.14M316.39M486.82M614.38M883.37M1.12B
Revenue Growth
3.68%46.38%53.87%26.20%43.78%27.07%
Gross Profit
115.53M177.60M305.30M377.77M542.06M675.00M
Gross Margin
53.45%56.13%62.71%61.49%61.36%60.13%
Operating Income
-28.17M-25.73M49.53M33.92M83.33M263.52M
Net Income
-42.60M-47.90M18.78M-18.52M78.34M120.79M
EPS
----7.899.40
EPS Growth
----51.73%19.08%
Forward PE
12.8614.7914.0410.7210.038.64
Free Cash Flow
-28.62M-38.70M114.36M42.67M119.42M197.73M
No. Analysts
-----7
EPS and Forward PE are based on non-GAAP adjusted numbers.

Revenue Forecast

Revenue202620272028
High1.2B
Avg1.1B
Low1.1B

Revenue Growth

Revenue Growth202620272028
High
30.7%
Avg
27.1%
Low
25.3%

EPS Forecast

EPS202620272028
High-
Avg9.40
Low-

EPS Growth

EPS Growth202620272028
High-
Avg
19.1%
Low-